Arcus Biosciences Inc
NYSE:RCUS

  • LAST PRICE
    14.5100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    13.0000/ 1
  • Ask / Lots
    16.0800/ 1
  • Open / Previous Close
    --- / 14.5100
  • Day Range
    ---
  • 52 Week Range
    13.4950
    20.3100
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Nov 12, 2024

      Show headlines and story abstract

    • 4:35PM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: RCUS

      Arcus Biosciences Announces New Employment Inducement Grants
      HAYWARD, Calif.--(BUSINESS WIRE)--November 12, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

  • Nov 6, 2024

      Show headlines and story abstract

    • 4:29PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: RCUS
      04:29 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:22PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: RCUS

      development and commercialization of its optioned molecules; difficulties associated with the management of the collaboration activities or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the "Risk Factors" section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law.

    • 4:22PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: RCUS

      development and commercialization of its optioned molecules; difficulties associated with the management of the collaboration activities or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the "Risk Factors" section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law.

Peers Headlines